• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
NBSE

NBSE

NeuBase Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.38

-0.01 (-1.56%)

Company Profile

CEO

Todd P. Branning

IPO Date

2004-05-28

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.38

Prev. Close

$0.38

Day Low

$0.36

Day High

$0.39

52W Low

$0.36

52W High

$4.44

Market Cap

$0.00B

Volume

0.09M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

47.2%

Avg Negative

9.1%

Avg Neutral

43.7%

News Feed

NeuBase Therapeutics Demonstrates Functional Rescue in Myotonic Dystrophy Type 1 Model and Allele-Selective Inhibition of KRAS Mutations to Inhibit Tumor Growth

GlobeNewsWire·6/8/2021·↑ positive

NeuBase Therapeutics Appoints Dr. Sandra Rojas-Caro Chief Medical Officer

GlobeNewsWire·5/20/2021·↑ positive

NeuBase Therapeutics to Participate in Upcoming Investor Conferences in May 2021

GlobeNewsWire·5/14/2021·↓ negative

NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewsWire·4/26/2021·↑ positive

NeuBase Therapeutics Announces Pricing of $40 Million Public Offering of Common Stock

GlobeNewsWire·4/22/2021·↑ positive

Why NeuBase Therapeutics Popped by 16.5% on Friday

The Motley Fool·1/22/2021·↑ positive

NeuBase Therapeutics' CEO, Dietrich A. Stephan, Ph.D.

Accesswire·12/18/2020·↑ positive

Newsbreak: New airline SKS Airways delays launch, aims for 4Q take-off

https://www.theedgemarkets.com·9/21/2020·↓ negative

NeuBase Therapeutics Reports Financial Results for the Third Fiscal Quarter of 2020

Yahoo·8/13/2020·↑ positive

Novavax Reported Promising Data on Covid-19 Vaccine. Its Stock Fell Anyway.

barrons·8/4/2020·↑ positive